Cargando…

CYP2C93/3 Gene Expression Affects the Total and Free Concentrations of Valproic Acid in Pediatric Patients with Epilepsy

PURPOSE: To perform therapeutic drug monitoring (TDM) of total and free plasma valproic acid (VPA) concentrations in pediatric patients with epilepsy and to analyze related factors. PATIENTS AND METHODS: Pediatric epileptic patients treated in 2015–2019 in our hospital were assessed. Total and free...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Xikun, Dong, Weichong, Li, Haoran, Yang, Xiuling, Jin, Yiran, Zhang, Zhiqing, Jiang, Ye
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8043849/ https://www.ncbi.nlm.nih.gov/pubmed/33859491 http://dx.doi.org/10.2147/PGPM.S301893

Ejemplares similares

The association of adjusted plasma valproic acid concentration with CYP2C9 gene polymorphism in patients with epilepsy: a systematic review and meta-analysis
por: Fang, Huihui, et al.
Publicado: (2021)

Safety range of free valproic acid serum concentration in adult patients
por: Tseng, Yu-Ju, et al.
Publicado: (2020)

Determination of the Optimal Concentration of Valproic Acid in Patients with Epilepsy: A Population Pharmacokinetic-Pharmacodynamic Analysis
por: Nakashima, Hiroo, et al.
Publicado: (2015)

RNA-seq analysis of blood of valproic acid-responsive and non-responsive pediatric patients with epilepsy
por: Wang, Yan, et al.
Publicado: (2019)

Hyperammonemia Associated with Valproic Acid Concentrations
por: Vázquez, Marta, et al.
Publicado: (2014)

Expression of Concern: Determination of the Optimal Concentration of Valproic Acid in Patients with Epilepsy: A Population Pharmacokinetic-Pharmacodynamic Analysis
Publicado: (2023)

The influence of CYP2C8*3 on carbamazepine serum concentration in epileptic pediatric patients
por: Milovanovic, DD, et al.
Publicado: (2016)

Valproic-induced Hyperammonemic Encephalopathy in a Known Case of Epilepsy
por: Imam, Syed F, et al.
Publicado: (2017)

Valproic Acid and Epilepsy: From Molecular Mechanisms to Clinical Evidences
por: Romoli, Michele, et al.
Publicado: (2019)

Valproic acid for children below 2 years of age with epilepsy
por: Muthaffar, Osama Y., et al.
Publicado: (2021)

CYP2C9 polymorphisms in epilepsy: influence on phenytoin treatment
por: Silvado, Carlos Eduardo, et al.
Publicado: (2018)

Early post-traumatic seizures are associated with valproic acid plasma concentrations and UGT1A6/CYP2C9 genetic polymorphisms in patients with severe traumatic brain injury
por: Sun, Yirui, et al.
Publicado: (2017)

Risk Factors of Hyperammonemia in Patients With Epilepsy Under Valproic Acid Therapy
por: Tseng, Yu-Lung, et al.
Publicado: (2014)

Gephyrin and CYP2C9 Genetic Polymorphisms in Patients with Pharmacoresistant Epilepsy
por: El-Tallawy, Hamdy N, et al.
Publicado: (2021)

Genetic and Non-genetic Factors Contributing to the Significant Variation in the Plasma Trough Concentration-to-Dose Ratio of Valproic Acid in Children With Epilepsy
por: Xu, Ze-Yue, et al.
Publicado: (2021)

Composite CYP3A (CYP3A4 and CYP3A5) phenotypes and influences on tacrolimus dose adjusted concentration in adult heart transplant recipients
por: Hernandez, Savine, et al.
Publicado: (2023)

Possible role of CYP2C9 & CYP2C19 single nucleotide polymorphisms in drug refractory epilepsy
por: Lakhan, Ram, et al.
Publicado: (2011)

Serum Alanine Transaminase Total Bilirubin Concentrations Predict CYP3A Activity as Measured by Midazolam and 1′-Hydroxylation
por: He, Rui, et al.
Publicado: (2015)

Evaluation of Cardiac Repolarization Indices in Epilepsy Patients Treated with Carbamazepine and Valproic Acid
por: Asoğlu, Ramazan, et al.
Publicado: (2020)

Replacement of Valproic Acid with New Anti-Seizure Medications in Idiopathic Generalized Epilepsy
por: Fujimoto, Ayataka, et al.
Publicado: (2022)

Overexpression of Homer1b/c induces valproic acid resistance in epilepsy
por: Wang, Yan, et al.
Publicado: (2022)

MicroRNA-221-3p Suppresses the Microglia Activation and Seizures by Inhibiting of HIF-1α in Valproic Acid-Resistant Epilepsy
por: Fu, Meng, et al.
Publicado: (2021)

Assessment of atherosclerotic risk among patients with epilepsy on valproic acid, lamotrigine, and carbamazepine treatment
por: Zuberi, Nudrat A., et al.
Publicado: (2017)

Genetic Analysis of CYP2C9 with Reference to Drug Response in Epilepsy Patients of Pakistan
por: Maqbool, Hafsa, et al.
Publicado: (2022)

Population Pharmacokinetics of Valproic Acid in Pediatric and Adult Caucasian Patients
por: Teixeira-da-Silva, Paulo, et al.
Publicado: (2022)

CYP3A4*22 and CYP3A5*3 are associated with increased levels of plasma simvastatin concentrations in the cholesterol and pharmacogenetics study cohort
por: Kitzmiller, Joseph P., et al.
Publicado: (2014)

Effect of CYP2C19 polymorphisms on serum valproic level acid in Chinese Han patients with schizophrenia
por: Wang, S., et al.
Publicado: (2021)

Functional Measurement of CYP2C9 and CYP3A4 Allelic Polymorphism on Sildenafil Metabolism
por: Tang, Peng-fei, et al.
Publicado: (2020)

MicroRNA-134 plasma levels before and after treatment with valproic acid for epilepsy patients
por: Wang, Xiaofeng, et al.
Publicado: (2017)

First‐line antiepileptic drug treatment in glioma patients with epilepsy: Levetiracetam vs valproic acid
por: van der Meer, Pim B., et al.
Publicado: (2021)

Association of ABCB1 Polymorphisms with Efficacy and Adverse Drug Reactions of Valproic Acid in Children with Epilepsy
por: Zhu, Jiahao, et al.
Publicado: (2023)

CYP3A5 and UGT1A9 Polymorphisms Influence Immunosuppressive Therapy in Pediatric Kidney Transplant Recipients
por: Krall, Paola, et al.
Publicado: (2021)

CYP3A4, CYP2C9 and CYP2B6 expression and ifosfamide turnover in breast cancer tissue microsomes
por: Schmidt, R, et al.
Publicado: (2004)

The Effects of H(2)S on the Activities of CYP2B6, CYP2D6, CYP3A4, CYP2C19 and CYP2C9 in Vivo in Rat
por: Wang, Xianqin, et al.
Publicado: (2013)

Three Patients Needing High Doses of Valproic Acid to Get Therapeutic Concentrations
por: Jackson, James, et al.
Publicado: (2015)

Transcriptome based differentiation of harmless, teratogenetic and cytotoxic concentration ranges of valproic acid
por: Stöber, Regina
Publicado: (2014)

Effect of CYP3A4*22, CYP3A5*3, and CYP3A combined genotypes on tamoxifen metabolism
por: Sanchez Spitman, A. B., et al.
Publicado: (2017)

AS3MT Polymorphism: A Risk Factor for Epilepsy Susceptibility and Adverse Drug Reactions to Valproic Acid and Oxcarbazepine Treatment in Children From South China
por: Fan, Xiaomei, et al.
Publicado: (2021)

CYP3A5∗3 and C3435T MDR1 Polymorphisms in Prognostication of Drug-Resistant Epilepsy in Children and Adolescents
por: Emich-Widera, Ewa, et al.
Publicado: (2013)

A Pediatric Covariate Function for CYP3A-Mediated Midazolam Clearance Can Scale Clearance of Selected CYP3A Substrates in Children
por: Brussee, Janneke M., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_kcb221u54uh7cjccjfn8p5ksqe